Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel serotonergic agents

D E Nichols1, D Marona-Lewicka, X Huang

  • 1Department of Medicinal Chemistry, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.

Drug Design and Discovery
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychedelics as Medicines: An Emerging New Paradigm.

Clinical pharmacology and therapeutics·2016
Same author

D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.

CNS & neurological disorders drug targets·2006
Same author

Distinct recognition of substrates by the human and Drosophila serotonin transporters.

The Journal of pharmacology and experimental therapeutics·2003
Same author

The implications of unfulfilled expectations and perceived pressure to attend the birth on men's stress levels following birth attendance: a longitudinal study.

Journal of psychosomatic obstetrics and gynaecology·2002
Same author

Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268.

Neuropharmacology·2002
Same author

Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.

Neuroscience·2002
Same journal

QSAR modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physicochemical descriptors.

Drug design and discovery·2004
Same journal

HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.

Drug design and discovery·2004
Same journal

Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes.

Drug design and discovery·2004
Same journal

Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.

Drug design and discovery·2004
Same journal

Predicting acyl-coenzyme A: cholesterol O-acyltransferase inhibitory activity: computational approach using topological descriptors.

Drug design and discovery·2004
Same journal

Conformational analysis of globomycin with a signal peptidase II inhibitory activity using molecular dynamics simulation.

Drug design and discovery·2004
See all related articles

Novel phenethylamines selectively releasing serotonin show therapeutic potential. Those releasing both serotonin and catecholamines are toxic, unlike selective serotonin agents.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Serotonin plays a crucial role in mood regulation and various neurological functions.
  • Understanding structure-activity relationships is key to developing targeted therapeutics.
  • Previous agents affecting serotonin have shown varying toxicity profiles.

Purpose of the Study:

  • To investigate the structure-activity relationships of substituted phenethylamines.
  • To identify compounds that selectively release neuronal serotonin.
  • To assess the neurotoxicity associated with serotonin and catecholamine release.

Main Methods:

  • Synthesis and characterization of substituted phenethylamine analogs.
  • In vitro assays to measure serotonin and catecholamine release.

Related Experiment Videos

  • Neurotoxicity assessments in rat brain models measuring serotonin markers.

    • Main Results:

    • Compounds releasing both serotonin and catecholamines demonstrated neurotoxicity to serotonin neurons.
    • Selective serotonin releasing agents (SSRAs) that do not affect catecholamines were found to be non-neurotoxic.
    • Preliminary structure-activity relationships were established for this class of compounds.

    Conclusions:

    • Selective serotonin releasing agents represent a promising class of compounds.
    • Targeting serotonin release selectively may avoid the neurotoxicity associated with broader catecholamine effects.
    • These SSRAs may offer therapeutic advantages over current serotonin uptake inhibitors in treating various disorders.